之江生物股价涨1.07%，大成基金旗下1只基金位居十大流通股东，持有90.92万股浮盈赚取19.09万元

Group 1 - The core viewpoint of the news is that Zhijiang Biotech's stock has shown a slight increase of 1.07%, reaching a price of 19.87 CNY per share, with a total market capitalization of 3.818 billion CNY [1] - Zhijiang Biotech, established on April 18, 2005, specializes in the research, production, and sales of molecular diagnostic reagents and equipment, with a significant revenue contribution from nucleic acid testing kits at 86.47% [1] - The company's revenue breakdown indicates that other products account for 11.99%, while molecular diagnostic instruments contribute 1.54% [1] Group 2 - Among the top circulating shareholders of Zhijiang Biotech, Dazhong Fund's Dazhong Jingheng Mixed A (090019) holds 909,200 shares, representing 0.47% of the circulating shares, with no change in the number of shares held compared to the previous period [2] - Dazhong Jingheng Mixed A has achieved a year-to-date return of 41.96% and a one-year return of 37.38%, ranking 1840 out of 8087 and 2005 out of 8085 in its category, respectively [2] - The fund manager, Su Bingyi, has a tenure of 13 years and 329 days, with the fund's total asset size at 1.9 billion CNY and a best return of 250.69% during his management period [2]